TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride with Hypofractionated Re-Irradiation Therapy in Treating Patients with Recurrent Glioblastoma Multiforme (GBM)

Diseases and Conditions Researched

Brain and Nervous System

What is the purpose of this trial?

This is a dose-escalation study that will assess the safety and determine the maximum tolerated dose (MTD) of mibefradil dihydrochloride, a partially selective T-type calcium channel blocker, combined with hypofractionated radiation therapy (RT) in subjects with recurrent glioblastoma multiforme (GBM).

Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Yale Cancer Center
Last Updated:
Study HIC#: 1406014067